Niccine, a nicotine vaccine, for relapse prevention: A phase ii, randomized, placebo-controlled, multicenter clinical trial

Nicotine and Tobacco Research

Volumn 15, Issue 9, 2013, Pages 1492-1501

  Tonstad, Serena ^a   Heggen, Eli ^a   Giljam, Hans ^b   Lagerbäck, Per Åke ^c   Tønnesen, Philip ^d   Wikingsson, Lena Degling ^e   Lindblom, Nina ^e   De Villiers, Sabina ^b   Svensson, Torgny H ^b   Fagerström, Karl Olov ^f  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Järfälla ^*  (Sweden)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e Independent Pharmaceutica AB   (Sweden)

^f Fagerstrom Consulting   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CARBON MONOXIDE; NICCINE; NICOTINE VACCINE; PLACEBO; UNCLASSIFIED DRUG; VARENICLINE; NICOTINE; VACCINE;

ABSTINENCE; ADULT; ARTICLE; CARBON MONOXIDE BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERSENSITIVITY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOTIVATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SMOKING CESSATION; WITHDRAWAL SYNDROME; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; CONTROLLED CLINICAL TRIAL; METHODOLOGY;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; SMOKING CESSATION; VACCINES;

EID: 84882693921     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntt003     Document Type: Article

References (25)

1. Buchhalter, A. R., Fant, R. V., & Henningfield, J. E. (2008). Novel pharmacological approaches for treating tobacco dependence and withdrawal. Drugs, 68, 1067-1088. doi:10.2165/00003495-200868080-00005
2. Cappelleri, J. C., Bushmakin, A. G., Baker, C. L., Merikle, E., Abayomi, O. O., & Gilbert, D. G. (2007). Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addictive Behaviors, 32, 912-923. doi:10.1016/j.addbeh.2006.06.028
3. Cerny, E. H., & Cerny, T. (2008). Anti-nicotine abuse vaccines in the pipeline: An update. Expert Opinion on Investigational Drugs, 17, 691-696. doi:10.4161/hv.5.4.7310
4. Cornuz, J., Zwahlen, S., Jungi, W. F., Osterwalder, J., Klingler, K., van Melle, G., Cerny, T. (2008). A vaccine against nicotine for smoking cessation: A randomized controlled trial. PLoS ONE, 3, e2547. doi:10.1371/journal.pone.0002547
5. Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001). Evaluation of the Brief Questionnaire of Smoking Urges (QSU-Brief) in laboratory and clinical settings. Nicotine & Tobacco Research, 3, 7-16. doi:10.1080/14622200020032051
6. Davis, H. L., McCluskie, M. J., Zhang, N., Benoit, M., Robertson, K., Pryde, D. C., Merson, J. R. (2012). NIC7-DT, a novel anti-nicotine vaccine, induces better functional antibody responses in mice compared to a NIC-Qβ mimetic [Abstract O10]. Helsinki, Finland: Society for Research on Nicotine and Tobacco.
7. De Villiers, S. H., Lindblom, N., Kalayanov, G., Gordon, S., Baraznenok, I., Malmerfelt, A., Svensson, T. H. (2010). Nicotine hapten structure, antibody selectivity and effect relationships: Results from a nicotine vaccine screening procedure. Vaccine, 28, 2161-2168. doi:10.1016/ j.vaccine.2009.12.051
8. De Villiers, S. H., Lindblom, N., Kalayanov, G., Gordon, S., Malmerfelt, A., Johansson, A. B., & Svensson, T. H. (2002). Active immunization against nicotine suppresses nicotineinduced dopamine release in the rat nucleus accumbens shell. Respiration, 69, 247-253. doi:10.1159/000063628
9. de Wit, H., Bodker, B., & Ambre, J. (1992). Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology, 10, 352-358. doi:10.1007/ BF02245161
10. Fagerström, K., Russ, C., Yu, C.-R., Yunis, C., & Foulds, J. (2012). The Fagerström test for nicotine dependence as a predictor of smoking abstinence: A pooled analysis of varenicline clinical trial data Nicotine & Tobacco Research, 14(12), 1467-1473. doi:10.1093/ntr/nts018
11. Hatsukami, D. K., Jorenby, D. E., Gonzales, D., Rigotti, N. A., Glover, E. D., Oncken, C. A., Rennard, S. I. (2011). Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clinical Pharmacology & Therapeutics, 89, 392-399. doi:10.1038/clpt.2010.317
12. Hatsukami, D. K., Rennard, S., Jorenby, D., Fiore, M., Koopmeiners, J., de Vos, A., Pentel, P. R. (2005). Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clinical Pharmacology & Therapeutics, 78, 456- 467. doi:10.1016/j.clpt.2005.08.007
13. Hieda, Y., Keyler, D. E., Van DeVoort, J. T., Niedbala, R. S., Raphael, D. E., Ross, C. A., & Pentel, P. R. (1999). Immunization of rats reduces nicotine distribution to brain. Psychopharmacology, 143, 150-157. doi:10.1007/ s002130050930
14. Hughes, J. R., & Hatsukami, D. (1986). Signs and symptoms of nicotine withdrawal. Archives of General Psychiatry, 43, 289-294. doi:10.1001/archpsyc.1986.01800030107013
15. Hukkanen, J., Jacob, P. 3rd, & Benowitz, N. L. (2005). Metabolism and disposition kinetics of nicotine. Pharmacological Review, 57, 79-115. doi:10.1124/pr.57.1.3
16. Keyler, D. E., Roiko, S. A., Benihabib, E., LeSage, M. G., St. Peter, J. V., Stewart, S., Pentel, P. R. (2005). Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: Dose- and affinity-response relationships. Drug Metabolism Disposition, 33, 1056-1061. doi:10.1124/ dmd.105.004234
17. Kitchens, C. M., & Foster, S. L. (2012). Nicotine conjugate vaccines: A novel approach in smoking cessation. Journal of the American Pharmacists Association, 52, 116-118. doi:10.1331/JAPhA.2012.12505
18. Lindblom, N., de Villiers, S. H., Kalayanov, G., Gorond, S., Johansson, A. M., & Svensson, T. H. (2002). Active immunization against nicotine prevents reinstatement of nicotine- seeking behavior in rats. Respiration, 69, 254-260. doi:10.1159/000063629
19. Malin, D. H. (2001). Nicotine dependence: Studies with a laboratory model. Pharmacology, Biochemistry and Behavior, 70, 551-559. doi:10.1016/S0091-3057(01)00699-2
20. Malin, D. H., Alvarado, C. L., Woodhouse, K. S., Karp, H., Urdiales, E., Lay, D., Fattom, A. (2002). Passive immunization against nicotine attenuates nicotine discrimination. Life Science, 70, 2793-2798. doi:10.1016. S0024-3025(02)01523-0
21. Malin, D. H., Moon, W. D., Goyarzu, T., Magallanes, N., Blair, M. B., Alexander, M. R., Fattom, A. (2010). Passive immunization against nicotine attenuates somatic nicotine withdrawal syndrome in the rat. Nicotine & Tobacco Research, 12, 438-444. doi:10.1093/ntr/ntq021
22. Martell, B. A., Mitchell, E., Poling, J., Gonsai, K., & Kosten, T. R. (2005). Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry, 58, 158-164. doi:10.1016/j.biopsych.2005.04.032
23. Nabi Biopharmaceuticals. Retrieved January 31, 2012, from www.nabi.com/pipeline/clinicaltrials.php Rose, J. (2008). Disrupting nicotine reinforcement. From cigarette to brain. Annals of the New York Academy of Science, 1141, 233-256. doi:10.1196/annals.1441.019
24. Tonstad, S., Tønnesen, P., Hajek, P., Williams, K. E., Billing, C. B., & Reeves, K. R. (2006). Effect of maintenance therapy with varenicline on smoking cessation. A randomized controlled trial. Journal of the American Medical Association, 296, 64-71. doi:10.1001/jama.296.1.64
25. Wagena, E. J., de Vos, A., Horwith, G., & van Schayck, C. P. (2008). The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: Results of a randomized, placebo-controlled phase 1-2 trial. Nicotine & Tobacco Research, 10, 213-218. doi:10.1080114622200701704921